Abiraterone
Melanoma, Cutaneous Malignant, Susceptibility To, 3
Explore 4 assets in Melanoma, Cutaneous Malignant, Susceptibility To, 3 →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05288166CT.gov A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma, Cutaneous Malignant, Susceptibility To, 3
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abiraterone (this asset) | Eli Lilly and Company | P3 | B · 60 |
| Prednisolone | Eli Lilly and Company | P3 | B |
| Prednisone | Eli Lilly and Company | P3 | B |
| Abemaciclib | Eli Lilly and Company | P3 | B |
Other indications for Abiraterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Carcinoma | — | P4 | BBB · 72 |
| Prostate Neoplasm | — | P3 | BB · 71 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abiraterone in Melanoma, Cutaneous Malignant, Susceptibility To, 3. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abiraterone-melanoma-cutaneous-malignant-susceptibility-to-3
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →